BVSHIGH SIGNALFINANCIAL10-K

BVS achieved a dramatic financial turnaround with operating income swinging from -$12.0M to $54.0M and net income moving from -$33.5M to $22.7M, while significantly strengthening its balance sheet.

This represents a fundamental shift from operating losses to strong profitability, indicating successful execution of business strategy and operational improvements. The concurrent 24.4% increase in stockholders' equity and 16.1% reduction in total liabilities demonstrates meaningful balance sheet deleveraging and financial health improvement that should enhance the company's strategic flexibility and creditworthiness.

Comparing 2026-03-05 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

BVS delivered exceptional financial performance with operating income improving by over 550% to reach $54.0M profitability from prior year losses, while net income turned positive at $22.7M. The company strengthened its balance sheet across multiple dimensions, increasing stockholders' equity by 24.4% to $184.1M, reducing total liabilities by 16.1%, and growing cash position by 23.2% to $51.2M. Operating cash flow nearly doubled to $74.7M while inventory decreased 11.1%, suggesting improved operational efficiency and working capital management that collectively signals a successful business transformation and stronger financial foundation.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+550.6%
-$12.0M$54.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+167.8%
-$33.5M$22.7M

Net income grew 167.8% — bottom-line growth signals improving overall business health.

Capital Expenditure
Cash Flow
+154.7%
$1.0M$2.6M

Capital expenditure jumped 154.7% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
+92.5%
$38.8M$74.7M

Operating cash flow surged 92.5% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
+24.4%
$147.9M$184.1M

Equity base grew 24.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
-23.8%
$210.4M$160.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
+23.2%
$41.6M$51.2M

Cash grew 23.2% — improving liquidity position supports investment and shareholder returns.

Total Liabilities
Balance Sheet
-16.1%
$542.4M$455.1M

Liabilities reduced 16.1% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-11.2%
$13.6M$12.1M

R&D spending cut 11.2% — could signal cost discipline or concerning reduction in innovation investment.

Inventory
Balance Sheet
-11.1%
$92.5M$82.2M

Inventory reduced 11.1% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-11
ADDED
As of February 27, 2026, there were 67,368,052 shares of Class A common stock outstanding and 15,786,737 shares of Class B common stock outstanding.
Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements including, without limitation, statements concerning: our future financial results and liquidity; our business strategy, position and operations; and expected sales trends, opportunities, market position and growth.
Table of C o ntents SUMMARY OF PRINCIPAL RISK FACTORS We are subject to several risks, including risks that may prevent us from achieving our business objectives or that may adversely affect our business, results of operations, financial condition, and cash flows.
Risk Factors , including the following principal risks: our 2025 Credit Agreement contains financial and operating restrictions that could limit our access to credit.
Our portfolio of products is comprised of five patient-focused areas, grouped into three businesses based on clinical use: (i) Pain Treatments PRP ( Pain Treatments ), (ii) Surgical Solutions and (iii) Restorative Therapies.
+7 more — sign up free →
REMOVED
As of February 27, 2025, there were 66,156,868 shares of Class A common stock outstanding and 15,786,737 shares of Class B common stock outstanding.
Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements including, without limitation, statements concerning our future financial results and liquidity; the impact of our recently divested Advanced Rehabilitation Business on our financial condition and operations; our business strategy, position and operations; and expected sales trends, opportunities, market position and growth.
Risk Factors , including the following principal risks: our Amended 2019 Credit Agreement contains financial and operating restrictions that may limit our access to credit.
We do not control the intellectual property rights covering these technologies and any loss of our rights to these technologies or the rights licensed to us could prevent us from selling our products; and our principal asset is our interest in BV LLC, and, accordingly, we depend on distributions from BV LLC to pay our taxes and expenses, including payments under the Tax Receivable Agreement.
BV LLC s ability to make such distributions may be subject to various limitations and restrictions.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →